Theme: India Pharma’s Digital Journey – The Progesss from Awareness to Adoption When: Wednesday, March 1, 2023, 7 PM to 9 PM Where: JW Marriott, Sahar Airport, Near Terminal 2 The pharmaceutical industry is in a conundrum as far as digital transformation is concerned. While on the one hand, the…
Measurement and optimization for digital marketing is one of the critical success factors in the pharmaceutical industry. At the moment it acts as a barrier to entry into digital marketing, but it should not. In the current market landscape, opportunities are arising to engage with healthcare professionals (HCPs) and patients through a multitude…
The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered.
The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model.
Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison.
‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product.
Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it.
A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it.
The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).
The customer is the one who buys a product from us. In pharmaceutical selling, the customer is not always the end user, but it can be a distributor or an intermediary (pharmacy). We have often heard that pharma marketing has to shift from Product to Customer. What does this mean?…
There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it?
“Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s.
The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest.
“Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.
Catalyzed by the pandemic, the pharma industry quickly progressed from being digitally agnostic to a state of preparedness.
The shift required the industry to experiment with technology in its customer-facing plans, which resulted in many cases the creation of random acts of digital, often without a cohesive overarching strategy.
Can pharma do better? The answer lies in understanding the utility of their digital assets while building a mindset to transform, and ensuring that teams within the organization do not work at cross-purposes.
A big myth about digital transformation is that it is all about technology. It is not. First, it is about thinking about how the business can grow faster and scale greater than it ever could in the past. It helps us to think of the true nature of technology. Second,…
It is heartening to see that Pharma marketers have finally decided to include digital into their marketing mix. Even if catalysed by Covid, this is good news Evan Schwartz called it “digital darwinism” – a phenomenon that caused technology to evolve faster than the society which adopts it. The average…
Salil Kallianpur The code of conduct for ethical pharmaceutical marketing was not designed for a world of data, software, and artificial intelligence. Already under severe pressure from COVID-19 and the changes that will lie in its wake, it is utterly inadequate to face the four main challenges that new technologies…
To me, patient centricity is as fascinating a concept as it is contradictory. It is fascinating because it puts power into the hands of the patient. And it is contradictory because pharma does not like giving away power over its messages or processes. Pharma has traditionally never enjoyed interaction and has depended on ‘pushing’ messages across rather than having ‘conversations’. It probably also explains why we make do with medical reps who are not the sharpest knives in the drawer and scarcely invest in sharpening them.